Floatz logo

Sra-333

Relapsing-Remitting Multiple Sclerosis

NeurognosticsPhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Relapsing-Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Natalizumab
Biogen
Phase 4BBB
PHYTONADIONE, (E)-(±)-
Biogen
Phase 4BBB
bg00002
Biogen
Phase 4BB
DACLIZUMAB
Biogen
Phase 3BB
Acetylsalicylic Acid
Biogen
Phase 4BB

View all 24 →

Same molecule, other indications

Sra-333 is also rated in:

Dementia With Lewy Bodies (DLB)Dormant
BBB
Indicative ·
76 / 100
View asset →
DementiaDormant
BBB
Indicative ·
74 / 100
View asset →
Alzheimer's DiseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →